Table 1 Distribution of insulin products in Bengaluru region, by insulin type, place of manufacture and marketing companies
a. Private-sector retail (N = 30) and hospital pharmacies (N = 5) | |||
| Â | Products Marketed by Indian companies (Biocon, Wockhardt, Lupin, Cadila, Nicholas Piramal, Ranbaxy) | Products Marketed by Non-Indian Companies (Novo Nordisk, Eli Lilly and Sanofi) | |
Place of Manufacture | INDIA | Total (N = 109) Human = 89.0% (n = 97) Analogue = 10.1% (n = 11) Porcine = 0.9% (n = 1) | Total (N = 159) Human = 81.1% (n = 129) Analogue = 18.2% (n = 29) Porcine = 0.6% (n = 1) |
OUTSIDE INDIA | Total (N = 0) | Total (N = 72) Human = 40.3% (n = 29) Analogue = 59.7% (n = 43) | |
b. Public-sector hospital pharmacies (n = 5) | |||
| Â | Products Marketed by Indian companies (Biocon, Lupin, Cadila Healthcare) | Products Marketed by Non-Indian Companies (Novo Nordisk, Eli Lilly and Sanofi) | |
Place of Manufacture | INDIA | Total (N = 11) Human = 81.8% (n = 9) Analogue = 18.2% (n = 2) | Total (N = 11) Human = 90.9% (n = 10) Analogue = 9.1% (n = 1) |
OUTSIDE INDIA | Total (N = 0) | Total (N = 6) Human = 33.3% (n = 2) Analogue = 66.7% (n = 4) | |